Covic Adrian, Ciumanghel Adi-Ionut, Siriopol Dimitrie, Kanbay Mehmet, Dumea Raluca, Gavrilovici Cristina, Nistor Ionut
Nephrology Department, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Division of Nephrology, Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
Int Urol Nephrol. 2017 Dec;49(12):2231-2245. doi: 10.1007/s11255-017-1698-4. Epub 2017 Sep 30.
Volume overload is a common complication in patients with end-stage kidney disease who undergo maintenance dialysis therapy and associated with hypertension, left ventricular hypertrophy and mortality in this population. Although bioimpedance analysis (BIA), an objective method to assess overhydration, is associated with poor outcomes in observational studies, in randomized controlled trials (RCTs) the results were conflicting. We have examined the role of BIA for assessing the "dry weight" and fluid status in order to improve fluid overload in comparison with a control or clinical-based prescription in patients with ESKD receiving haemodialysis or peritoneal dialysis.
All RCTs and quasi-RCTs in which BIA was used to improve fluid overload and assess the effect on all-cause mortality, cardiovascular morbidity, systolic blood pressure and volume control and arterial stiffness were included.
Seven RCTs with 1312 patients could be included in this review. In low-to-medium quality of the evidence, the use of BIA did not reduce all-cause mortality (relative risk 0.87, 95% CI 0.54-1.39) and had small to no effect on body change, but it improved systolic blood pressure control (mean difference (MD) -2.73 mmHg, 95% CI -5.00 to -0.46 mmHg) and reduce overhydration, as measured by BIA, with 0.43 L [(MD), 95% CI 0.71-0.15 L].
In ESKD patients, BIA-based interventions for correction of overhydration have little to no effect on all-cause mortality, whereas BIA improved systolic blood pressure control. Our results should be interpreted with caution as the size and power of the included studies are low. Further studies, larger or with a longer follow-up period, should be performed to better describe the effect of BIA-based strategies on survival.
容量超负荷是接受维持性透析治疗的终末期肾病患者常见的并发症,与该人群的高血压、左心室肥厚及死亡率相关。尽管生物电阻抗分析(BIA)作为一种评估水合过多的客观方法,在观察性研究中与不良结局相关,但在随机对照试验(RCT)中结果却相互矛盾。我们研究了BIA在评估“干体重”和液体状态方面的作用,以便与接受血液透析或腹膜透析的终末期肾病患者基于对照或临床的处方相比,改善液体超负荷情况。
纳入所有使用BIA改善液体超负荷并评估其对全因死亡率、心血管疾病发病率、收缩压、容量控制及动脉僵硬度影响的RCT和准RCT。
本综述纳入了7项RCT,共1312例患者。在低至中等质量的证据下,使用BIA并未降低全因死亡率(相对风险0.87,95%可信区间0.54 - 1.39),对身体变化影响较小或无影响,但改善了收缩压控制(平均差值(MD)-2.73 mmHg,95%可信区间-5.00至-0.46 mmHg),并通过BIA测量减少了0.43 L的水合过多情况[(MD),95%可信区间0.71 - 0.15 L]。
在终末期肾病患者中,基于BIA的纠正水合过多的干预措施对全因死亡率影响很小或无影响,而BIA改善了收缩压控制。由于纳入研究的规模和效能较低,我们的结果应谨慎解读。应开展更大规模或随访期更长的进一步研究,以更好地描述基于BIA的策略对生存的影响。